Global Parkinson's Disease (PD) Drugs Market 2017-2021 - Product Image

Global Parkinson's Disease (PD) Drugs Market 2017-2021

  • ID: 4380329
  • Report
  • Region: Global
  • 85 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Biogen
  • Eli Lilly
  • H. Lundbeck
  • Novartis
  • Prana Biotechnology
  • MORE
About Parkinson's Disease (PD) Drugs

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.

The analysts forecast the global parkinson's disease (PD) drugs market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global parkinson's disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Parkinson's Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
Other prominent vendors
  • AbbVie
  • Abital Pharma
  • Addex Therapeutics
  • Biogen
  • Eisai
  • Eli Lilly
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Impax Laboratories
  • Kyowa Hakko Kirin
  • Otsuka Pharmaceutical
  • Pfizer
  • Prana Biotechnology
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Takeda Pharmaceutical
  • UCB
Market drivers
  • Rise in geriatric population
  • For a full, detailed list, view the full report
Market challenges
  • Entry of generics
  • For a full, detailed list, view the full report
Market trends
  • Emergence of biomarkers
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Biogen
  • Eli Lilly
  • H. Lundbeck
  • Novartis
  • Prana Biotechnology
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation by drug class
  • Dopamine agonist
  • MAO inhibitors
  • AChE inhibitors
  • Glutamate inhibitors
  • Others
PART 08: Market segmentation based on geography
  • PD drugs market in Americas
  • PD drugs market in EMEA
  • PD drugs market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Emergence of biomarkers
  • Gene therapy to reverse the progression of PD
  • Advancing biomedical science
  • Focus on regenerative therapies for mental disorders
  • High growth potential of mAbs
PART 12: Vendor landscape
  • Competitive scenario
  • Key news
PART 13: Key vendor analysis
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global PD drugs market: A snapshot
Exhibit 02: Global PD drugs market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis of global PD drugs market
Exhibit 04: Five forces analysis
Exhibit 05: Pipeline landscape based on number of molecules, 2016
Exhibit 06: Key clinical trials
Exhibit 07: Segmentation of global PD drugs market by drug class 2016
Exhibit 08: Global PD drugs market share by drug class 2016
Exhibit 09: Global PD dopamine agonist drugs market 2016-2021 ($ millions)
Exhibit 10: Global PD MAO inhibitors drugs market 2016-2021 ($ millions)
Exhibit 11: Global PD AchE inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Global PD glutamate inhibitors drugs market 2016-2021 ($ millions)
Exhibit 13: Segmentation of global PD drugs market share by geography 2016 and 2021 (%)
Exhibit 14: Global PD drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 15: Global PD drugs market share by geography 2016-2021 (%)
Exhibit 16: PD drugs market scenario in different regions
Exhibit 17: Market scenario in Americas
Exhibit 18: PD drugs market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: PD drugs market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: PD drugs market in APAC 2016-2021 ($ millions)
Exhibit 23: Geriatric population analysis and estimates in 2000 and 2030 (millions)
Exhibit 24: Revenue erosion of PD drugs after loss of exclusivity
Exhibit 25: Planned clinical trials of iPS cell-based therapies
Exhibit 26: Competitive structure analysis of global PD drugs market 2016
Exhibit 27: Boehringer Ingelheim: Key highlights
Exhibit 28: Boehringer Ingelheim: Strength assessment
Exhibit 29: Boehringer Ingelheim: Strategy assessment
Exhibit 30: Boehringer Ingelheim: Opportunity assessment
Exhibit 31: GlaxoSmithKline: Key highlights
Exhibit 32: GlaxoSmithKline: Strength assessment
Exhibit 33: GlaxoSmithKline: Strategy assessment
Exhibit 34: GlaxoSmithKline: Opportunity assessment
Exhibit 35: Novartis: Key highlights
Exhibit 36: Novartis: Strength assessment
Exhibit 37: Novartis: Strategy assessment
Exhibit 38: Novartis: Opportunity assessment
Exhibit 39: Teva Pharmaceutical Industries: Key highlights
Exhibit 40: Teva Pharmaceutical Industries: Strength assessment
Exhibit 41: Teva Pharmaceutical Industries: Strategy assessment
Exhibit 42: Teva Pharmaceutical Industries: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Biogen
  • Eli Lilly
  • H. Lundbeck
  • Novartis
  • Prana Biotechnology
  • MORE
New Report Released: - Global Parkinson's Disease (PD) Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global parkinson's disease (PD) drugs market: Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.

Commenting on the report, an analyst from the research team said: “One trend in the market is emergence of biomarkers. The global PD drugs market is primarily dominated by dopamine agonist, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others. Use of these drugs for the treatment of different types of neurodegenerative disorders such as Lewy bodies dementia, movement disorder, and PD indicates that these disorders have common pathological conditions.”

According to the report, one driver in the market is rise in geriatric population. PD is a neurological disorder, often characterized by a decline in motor functions, cognitive, and memory impairments. The cognitive impairment associated with PD may include symptoms such as memory loss, difficulty in understanding words, inability to carry out voluntary activities, failure to identify objects, and others. The risk of developing PD increases with age and is more common among older people. As per the CDC, the projected demographic changes in the US and increasing geriatric population demand better understanding of the pathogenesis of various neurological diseases, including dementia, among older population and is a growing public health concern.

Further, the report states that one challenge in the market is entry of generics. Generic drugs are often introduced once the patent on the branded drugs expires. Patent expiries led to the introduction of less expensive generic drugs in the market. The global PD drugs market has also witnessed the loss of patent exclusivity period of various blockbuster drugs, which has led to the entry of generics during the forecast period. Many generic products currently serve the market. For instance, the patent expiry of top-selling drugs such as Aricept from Eisai has led to decrease in the revenue potential of the market in the recent years, and entry of generic donepezil are hampering the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
  • AbbVie
  • Abital Pharma
  • Addex Therapeutics
  • Biogen
  • Eisai
  • Eli Lilly
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Impax Laboratories
  • Kyowa Hakko Kirin
  • Otsuka Pharmaceutical
  • Pfizer
  • Prana Biotechnology
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Takeda Pharmaceutical
  • UCB
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll